What is Abbott's noncontrolling interests in subsidiaries?

Abbott (ABT) reported noncontrolling interests in subsidiaries of $640M in Q1 2026.

How has Abbott's noncontrolling interests in subsidiaries changed year-over-year?

Abbott's noncontrolling interests in subsidiaries increased by 153.0% year-over-year, from $253M to $640M.

What is the long-term trend for Abbott's noncontrolling interests in subsidiaries?

Over 5 years (2020 to 2025), Abbott's noncontrolling interests in subsidiaries has grown at a 24.0% compound annual growth rate (CAGR), from $219M to $641M.

Abbott ABT Noncontrolling interests in subsidiaries

Noncontrolling interests in subsidiaries at other companies

Boston ScientificBSX

$240M+3.0%

CencoraCOR

$187.36M+12.2%

MedtronicMDT

——

Medline, Inc. MDLN

——

DanaherDHR

——

Merck & Co.MRK

——

Other financials

Income statement

See full

Revenue$11.2B+7.8%

Gross profit$6.3B+6.5%

Operating income$1.3B-20.6%

Net income$1.1B-18.7%

EPS (diluted)$0.61-19.7%

Balance sheet

See full

Cash & equivalents$6.8B+4.2%

Total debt$34.0B+157%

Total equity$52.1B+6.7%

Total assets$110.43B+35.6%

Cash flow

See full

Operating cash flow$1.3B-7.2%

CapEx$399.0M-17.6%

Free cash flow$916.0M-1.8%

Valuation

See full

Market cap$154.15B-22.5%

Enterprise value$181.39B-13.1%

P/E24.6×+9.8×

P/S3.4×-1.3×

Profitability

See full

Gross margin56.3%+0.4pp

Operating margin17.1%+0.2pp

Net margin13.9%-18.0pp

Returns & leverage

See full

Return on equity12.4%-18.4pp

Debt / equity0.7×+0.4×

Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:MinorityInterest.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's noncontrolling interests in subsidiaries.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Abbott's noncontrolling interests in subsidiaries?: Abbott (ABT) reported noncontrolling interests in subsidiaries of $640M in Q1 2026.
How has Abbott's noncontrolling interests in subsidiaries changed year-over-year?: Abbott's noncontrolling interests in subsidiaries increased by 153.0% year-over-year, from $253M to $640M.
What is the long-term trend for Abbott's noncontrolling interests in subsidiaries?: Over 5 years (2020 to 2025), Abbott's noncontrolling interests in subsidiaries has grown at a 24.0% compound annual growth rate (CAGR), from $219M to $641M.